Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS Metformin and intensive lifestyle changes (ILC) reduced the incidence of type 2 diabetes (T2D) versus standard care (control) in overweight or obese subjects with impaired glucose tolerance (IGT) in the Diabetes Prevention Program (DPP) trial and Diabetes Prevention Program Outcomes Study (DPPOS). We projected lifetime clinical and economic outcomes based on the results from the DPP+DPPOS, from a 3rd-party payer perspective in Australia. METHODS A semi-Markov, 2nd-order Monte Carlo model was developed with four health states: "normal glucose regulation" (NGR); IGT; T2D and 'dead'. Outcomes were discounted at 5% annually. Univariate and probabilistic sensitivity analyses were performed. Incremental cost-effectiveness ratios (ICERs) were calculated. RESULTS Cumulative incidence (standard deviation) of T2D was 89.7% (0.2), 83.8% (0.2) and 73.4% (0.3%) for control, metformin and ILC respectively. Lifetime incremental direct costs were $1217 (4411) per subject for metformin versus control, with cost savings of $289 (4296) for ILC versus control. ILC therefore dominated control, with improvements in clinical outcomes and overall cost savings. Incremental costs per QALY-gained for metformin versus control were $10,142. Probability of cost-effectiveness at willingness-to-pay threshold of $50,000 was 78% and 100% for metformin or ILC respectively. Results were most sensitive to probabilities of developing T2D and costs of implementing the interventions. CONCLUSIONS/INTERPRETATION Substantial improvements in lifetime clinical outcomes could be expected in high risk subjects treated with metformin or ILC. Prevention of T2D in this group of subjects is good value for money, and may even lead to long term cost savings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Weinstein, M. C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., & Luce, B. R. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00234.x · Cited by 1,172
Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993
Gu, K., Cowie, C. C., & Harris, M. I. (1998) · Diabetes Care · doi:10.2337/diacare.21.7.1138 · Cited by 881
Cited by
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Zhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0018 · Cited by 173
Review of Metformin Use for Type 2 Diabetes Prevention
Moin, T., Schmittdiel, J. A., Flory, J. H., Yeh, J., Karter, A. J., Kruge, L. E., Schillinger, D., Mangione, C. M., Herman, W. H., & Walker, E. A. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.04.038 · Cited by 75
Decision models of prediabetes populations: A systematic review
Leal, J., Morrow, L. M., Khurshid, W., Pagano, E., & Feenstra, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13684 · Cited by 30
Gordon, L. G., Bird, D., Oldenburg, B., Friedman, R. H., Russell, A. W., & Scuffham, P. A. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.032 · Cited by 23
Metadata
- Authors
- Palmer, A. J., & Tucker, D. M. D.
- Venue
- Primary Care Diabetes
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 6
- Issue
- 2
- Pages
- 109-121
- ISSN
- 1751-9918 (ISSN-L)
- OpenAlex
- W2058798676
- Cited by
- 53
- References
- 19
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis. https://app.cochat.ai/papers/10.1016/j.pcd.2011.10.006
- The paper
- Palmer, A. J., & Tucker, D. M. D. (2012). Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis. Primary Care Diabetes. https://doi.org/10.1016/j.pcd.2011.10.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.